ライフサイエンスコーパス: sustained virologic response

1 er the last planned dose of study treatment (sustained virologic response).

2 ctable HCV RNA by Abbott RealTime achieved a sustained virologic response.

3 the month following enrollment and achieving sustained virologic response.

4 of the 116 patients receiving placebo had a sustained virologic response.

5 ents and ribavirin resulted in high rates of sustained virologic response.

6 as associated with a greater likelihood of a sustained virologic response.

7 dverse events; three of these patients had a sustained virologic response.

8 notype 3 infection resulted in high rates of sustained virologic response.

9 ng to adverse events after week 18 but had a sustained virologic response.

10 herapy, n=3; IFN/ribavirin, n=11); all had a sustained virologic response.

11 iviral treatment, of whom 165 (17%) achieved sustained virologic response.

12 All patients achieved sustained virologic response.

13 able macrophage MxA staining, only one had a sustained virologic response.

14 rols) (all, P < .0001), without increases in sustained virologic response.

15 f the 31 patients treated, 30 (97%) achieved sustained virologic response.

16 atients during treatment and after achieving sustained virologic response.

17 baseline resistance polymorphisms achieved a sustained virologic response.

18 Of the 13 patients who did not have a sustained virologic response, 10 had a relapse after the

19 Primary endpoint was sustained virologic response 12 weeks after end of treat

20 icantly superior to placebo and PR; rates of sustained virologic response 12 weeks after planned end

21 otype (GT)1-infected patients, high rates of sustained virologic response 12 weeks after planned end

22 The primary end point was a sustained virologic response 12 weeks after the completi

23 The sustained virologic response 12 weeks after the completi

24 Rates of a sustained virologic response 12 weeks after the completi

25 The rate of a sustained virologic response 12 weeks after the completi

26 The primary end point was the rate of sustained virologic response 12 weeks after the end of s

27 The primary endpoint was sustained virologic response 12 weeks after the end of t

28 The primary efficacy end point was a sustained virologic response 12 weeks after the end of t

29 had an extended rapid virologic response; a sustained virologic response 12 weeks after the end of t

30 point was the percentage of patients with a sustained virologic response 12 weeks after the end of t

31 The primary end point was a sustained virologic response 12 weeks after the end of t

32 04 patients had detectable HCV RNA following sustained virologic response 12 weeks after the end of t

33 nce of late recurrent viremia (patients with sustained virologic response 12 weeks after the end of t

34 Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of t

35 The primary efficacy endpoint was sustained virologic response 12 weeks after the end of t

36 The primary endpoint was sustained virologic response 12 weeks after the end of t

37 The primary efficacy end point was sustained virologic response 12 weeks after therapy (SVR

38 vestigated whether patients who maintained a sustained virologic response 12 weeks after therapy (SVR

39 rapid virologic response, and 8 (47%) had a sustained virologic response 12 weeks after therapy; 6 p

40 dpoint was the percentage of patients with a sustained virologic response 12 weeks after treatment (S

41 Sustained virologic response 12 weeks after treatment (S

42 = 564; CTP class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (S

43 The primary end point was sustained virologic response 12 weeks after treatment (S

44 lyzed to assess completion of treatments and sustained virologic response 12 weeks after treatment (S

45 The primary endpoint was sustained virologic response 12 weeks after treatment (S

46 ithout ribavirin, demonstrated high rates of sustained virologic response 12 weeks after treatment en

47 Sustained virologic response 12 weeks after treatment wa

48 The primary end point was sustained virologic response 12 weeks after treatment.

49 Sustained virologic response 12 weeks post-treatment (SV

50 observational study to determine real-world sustained virologic responses 12 weeks after treatment (

51 A higher percentage of patients achieved a sustained virologic response 24 weeks after therapy ende

52 We report the rate of sustained virologic response 24 weeks after therapy.

53 oup and 140 (88%) in the T12PR48 group had a sustained virologic response (absolute difference, 4 per

54 us sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97

55 Rates of sustained virologic response across all genotypes were 9

56 The rates of sustained virologic response across all treatment subgro

57 ts with chronic HCV infection who achieved a sustained virologic response after 12 weeks of treatment

58 for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with

59 h residual HCV-RNA in the explant achieved a sustained virologic response after receiving their liver

60 Sustained virologic response after treatment among HCV-i

61 fected with HCV genotype 1 who had not had a sustained virologic response after treatment with pegint

62 epatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regime

63 patasvir for 12 weeks provided high rates of sustained virologic response among both previously treat

64 of serious adverse events and a high rate of sustained virologic response among liver-transplant reci

65 ir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV g

66 sofosbuvir was associated with high rates of sustained virologic response among patients infected wit

67 The rate of sustained virologic response among patients receiving so

68 vir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV gen

69 The study regimen resulted in high rates of sustained virologic response among patients with HCV gen

70 r 8 weeks was associated with a high rate of sustained virologic response among previously untreated

71 hibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated

72 ribavirin was associated with high rates of sustained virologic response among previously untreated

73 tect any significant differences in rates of sustained virologic response among the three study group

74 The primary efficacy end point was a sustained virologic response (an HCV RNA level of <25 IU

75 The primary end point was a sustained virologic response (an HCV RNA level of <25 IU

76 ologic response (CVR) included pretransplant sustained virologic response and post-transplant virolog

77 to IL28B CC genotype, likelihood of RVR and sustained virologic response, and BOC/TVR prices.

78 tic approaches are far from optimal, because sustained virologic responses are only achieved in one-t

79 Primary endpoints included sustained virologic response as defined as negative vira

80 d dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports

81 Failed DAA/PR Therapy) demonstrated a 96.2% sustained virologic response at 12 weeks (SVR12) rate us

82 Sustained virologic response at 12 weeks (SVR12).

83 </=15 IU/mL 12 weeks after stopping therapy (sustained virologic response at 12 weeks [SVR12]).

84 s than 25 IU/mL at 12 weeks after treatment (sustained virologic response at 12 weeks [SVR12]).

85 us while on therapy and 100% have achieved a sustained virologic response at 12 weeks after completio

86 int was the proportion of patients achieving sustained virologic response at 12 weeks after the cessa

87 The primary end point was sustained virologic response at 12 weeks after the end o

88 The primary end point was a sustained virologic response at 12 weeks after the end o

89 Overall, 322 patients (96%) had a sustained virologic response at 12 weeks after the end o

90 The primary end point was sustained virologic response at 12 weeks after the end o

91 The primary end point was a sustained virologic response at 12 weeks after the end o

92 The primary end point was sustained virologic response at 12 weeks after the end o

93 the two studies, the primary end point was a sustained virologic response at 12 weeks after the end o

94 The primary endpoint was sustained virologic response at 12 weeks after the end o

95 The primary endpoint was sustained virologic response at 12 weeks after the end o

96 e primary end point for the two trials was a sustained virologic response at 12 weeks after the end o

97 The primary efficacy end point was sustained virologic response at 12 weeks after therapy (

98 The primary end point was sustained virologic response at 12 weeks after therapy e

99 Measurements: The primary end point was sustained virologic response at 12 weeks after therapy e

100 The primary end point was a sustained virologic response at 12 weeks after therapy.

101 notype 1a and 2 of 2 with genotype 1b) had a sustained virologic response at 12 weeks after treatment

102 All 10 patients in group B had a sustained virologic response at 12 weeks after treatment

103 dpoint was the percentage of patients with a sustained virologic response at 12 weeks posttreatment.

104 Per protocol rates of sustained virologic response at 12 weeks were 98.1% (622

105 The 2 patients who did not achieve sustained virologic response at 12 weeks were lost to fo

106 fidence interval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 o

107 dence interval 93%-100%) of patients reached sustained virologic response at 12 weeks.

108 The primary end point was sustained virologic response at 24 weeks after the end o

109 mg of ritonavir) plus ribavirin, the rate of sustained virologic response at 24 weeks after treatment

110 nse at 12 weeks after treatment, and 9 had a sustained virologic response at 24 weeks after treatment

111 eron alfa-2a and ribavirin for 8 weeks had a sustained virologic response at 24 weeks, as did 6 of 10

112 no response to previous therapy (10%) had a sustained virologic response at 24 weeks.

113 s and interferon for 4, 8, or 12 weeks had a sustained virologic response at 24 weeks.

114 530 (NS5A inhibitor) has shown high rates of sustained virologic response at post-treatment week 12 (

115 nts who received 24 weeks of treatment had a sustained virologic response at post-treatment week 12,

116 nts who received 12 weeks of treatment had a sustained virologic response at post-treatment week 12,

117 ive-regimen group, 286 of 297 patients had a sustained virologic response at post-treatment week 12,

118 Of the 34 study participants, 33 had a sustained virologic response at post-treatment weeks 12

119 Sustained virologic response at posttreatment week 12 (S

120 endpoint was the percentage of patients with sustained virologic response at posttreatment week 12 (S

121 The primary efficacy measure was sustained virologic response at posttreatment week 12 (S

122 By intent-to-treat analysis, sustained virologic response at posttreatment week 12 wa

123 response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of

124 One hundred percent of patients exhibited sustained virologic response at week 12 after the end of

125 The primary end point was a sustained virologic response at week 12 after the end of

126 Proportion of patients with sustained virologic response at week 12 after treatment

127 High rates of sustained virologic response at week 12 were observed am

128 18 patients with genotype 3 infection had a sustained virologic response at week 12.

129 ad a response to prior therapy showed that a sustained virologic response can be achieved with two di

130 56% (CI, 46% to 66%) of patients achieved a sustained virologic response compared with 46% (CI, 37%

131 r treatment durations and increased rates of sustained virologic response compared with existing ther

132 During the OPERA-1 study, 3 patients had a sustained virologic response; deep sequencing indicated

133 A sustained virologic response, defined as an undetectable

134 Reinfection after sustained virologic response has been reported, but is t

135 sessment was the proportion of patients with sustained virologic response (HCV RNA <25 IU/mL) at post

136 The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of

137 itiation (HR = 1.002; P = .04) and lack of a sustained virologic response (HR = 2.1; P = .04).

138 iation (HR = 1.003; P = .005), and lack of a sustained virologic response (HR = 3.3; P = .04).

139 t ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study involvin

140 l-oral HCV regimens have shown high rates of sustained virologic response in both clinical trials and

141 ospective studies demonstrated high rates of sustained virologic response in children with chronic he

142 The rate of sustained virologic response in each group was compared

143 The rate of sustained virologic response in group A was 96.2% (95% c

144 red direct-acting agents to achieve complete sustained virologic response in humans.

145 ibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically inf

146 fosbuvir for 12 weeks provided high rates of sustained virologic response in patients coinfected with

147 ived antiviral therapy, with higher rates of sustained virologic response in patients with genotype 2

148 asvir for 24 weeks resulted in high rates of sustained virologic response in patients with HCV infect

149 svir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or

150 in resulted in significantly higher rates of sustained virologic response in previously treated patie

151 As compared with the rate of sustained virologic response in the group that received

152 ng patients with HCV genotype 3, the rate of sustained virologic response in the sofosbuvir-velpatasv

153 ng patients with HCV genotype 2, the rate of sustained virologic response in the sofosbuvir-velpatasv

154 These drugs substantially increased rates of sustained virologic response in treatment-naive and -exp

155 virus (HCV) infection, increase the rates of sustained virologic response in treatment-naive persons

156 uvir plus ledipasvir for 12 weeks achieved a sustained virologic response, including 7 with advanced

157 Early and sustained virologic responses increased with higher leve

158 events were observed in the 51 patients with sustained virologic response (n = 36) and relapse (n = 1

159 edian time of 12 weeks of therapy; all had a sustained virologic response (no detectable serum HCV RN

160 Among 282 subjects who did not achieve sustained virologic response, no novel sofosbuvir resist

161 Sustained virologic response occurred in 74% (28 in 38)

162 al load 24 weeks after treatment completion (sustained virologic response of 24 weeks [SVR24]).

163 genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.

164 psychiatric diseases do not differ regarding sustained virologic response or IFN-alpha-associated com

165 notherapy, combination therapy had a greater sustained virologic response rate (64% vs. 33%; relative

166 The overall sustained virologic response rate 12 weeks after the end

167 The sustained virologic response rate among those with compl

168 Sustained virologic response rate and adverse event-rela

169 and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN

170 n plus low-dose ribavirin achieved a greater sustained virologic response rate than pegylated interfe

171 the modern treatment of HCV have boosted the sustained virologic response rate to about 80%, a 30% in

172 The sustained virologic response rate was 98% (102 of 104 pa

173 highest risk of advanced fibrosis and lowest sustained virologic response rate.

174 Empirical cross-trial data indicated high sustained virologic response rates (>90%) in prior relap

175 ral agents have revolutionized therapy, with sustained virologic response rates (undetectable viral l

176 e-1 infected patients significantly improved sustained virologic response rates and the potential for

177 patitis C viral protease inhibitors increase sustained virologic response rates compared to interfero

178 te hepatitis C (AHC) is more effective, with sustained virologic response rates greater than 90%.

179 on and ribavirin have dramatically increased sustained virologic response rates in genotype 1-infecte

180 Although some studies have suggested higher sustained virologic response rates in HCV-infected women

181 With or without concomitant antiretrovirals, sustained virologic response rates were higher in patien

182 but not statistically significant, early and sustained virologic response rates with vaniprevir, as c

183 The primary end point was sustained virologic response (serum HCV RNA <25 IU/mL) 1

184 In the sustained virologic response (SVR) (36) and spontaneousl

185 If this cohort had a 90% rate of sustained virologic response (SVR) 4 weeks after treatme

186 s C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of tre

187 Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon a

188 Achievement of a sustained virologic response (SVR) after treatment for H

189 tle is known about factors associated with a sustained virologic response (SVR) among patients with h

190 ese anemia management strategies on rates of sustained virologic response (SVR) and safety.

191 Rates of sustained virologic response (SVR) at 12 weeks were avai

192 Pre-treatment predictors of sustained virologic response (SVR) at 24 weeks following

193 with genotype 1 chronic hepatitis C attain a sustained virologic response (SVR) at only approximately

194 act of psychoeducation (PE) on retention and sustained virologic response (SVR) during HCV therapy am

195 nation of antiviral treatment, patients with sustained virologic response (SVR) had improved signific

196 s recommend continued HCC surveillance after sustained virologic response (SVR) has been achieved.

197 Antiviral treatment with sustained virologic response (SVR) improves survival in

198 s (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patient

199 is (ALF) in CHC treatment-naive patients and sustained virologic response (SVR) in CHC patients on pe

200 The current standard for determining sustained virologic response (SVR) in patients treated f

201 We evaluated the benefit of sustained virologic response (SVR) in patients with HCV

202 alpha (IFN-alpha) and ribavirin can induce a sustained virologic response (SVR) in some but not all h

203 svir, and dasabuvir to produce high rates of sustained virologic response (SVR) in these patients.

204 The sustained virologic response (SVR) in treatment-naive pa

205 Multivariate models of sustained virologic response (SVR) included age, race, c

206 The aim of this study was to assess sustained virologic response (SVR) of LDV/SOF+/-ribaviri

207 ed pegylated IFN plus ribavirin therapy with sustained virologic response (SVR) or nonresponse (NR) w

208 al blood from patients who achieved either a sustained virologic response (SVR) or relapsed.

209 (RBV) significantly increases the chances of sustained virologic response (SVR) over treatment with P

210 The sustained virologic response (SVR) rate and predictors o

211 able/BLOQ HCV RNA, on average, had a reduced sustained virologic response (SVR) rate compared with su

212 Six DAA regimens showed high sustained virologic response (SVR) rates (>95%) in patie

213 ibavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with mini

214 High sustained virologic response (SVR) rates have been obser

215 f the literature on treatment completion and sustained virologic response (SVR) rates in DUs.

216 was to compare baseline characteristics and sustained virologic response (SVR) rates in patients inc

217 Sustained virologic response (SVR) rates measured 24 wee

218 plus ribavirin for 24 weeks, which leads to sustained virologic response (SVR) rates of 65%-80%.

219 cting antivirals (DAAs) for 6 weeks achieves sustained virologic response (SVR) rates of 95% in some

220 and ribavirin (RBV) significantly increases sustained virologic response (SVR) rates over PegIFN/RBV

221 SOF/RBV costs approximately US$169,000, with sustained virologic response (SVR) rates ranging from 52

222 ment-naive patients, prospectively predicted sustained virologic response (SVR) rates that were compa

223 Sustained virologic response (SVR) rates were 32%, 50%,

224 Sustained virologic response (SVR) rates were 56%, 72%,

225 Sustained virologic response (SVR) rates were 64% (T12/P

226 Sustained virologic response (SVR) rates with pegylated

227 rapy, patients with POAE had a lower rate of sustained virologic response (SVR) than those without PO

228 The long-term effect of sustained virologic response (SVR) to antiviral therapy

229 thnicity were associated with lower rates of sustained virologic response (SVR) to interferon-based t

230 n are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (Pe

231 of this study was to determine the impact of sustained virologic response (SVR) to pegylated interfer

232 baseline HOMA-IR and pretreatment factors on sustained virologic response (SVR) to telaprevir (TVR) i

233 nterferon alpha plus ribavirin treatment and sustained virologic response (SVR) was determined 6-9 mo

234 ce interval [CI], .33-.57) and attainment of sustained virologic response (SVR) were associated with

235 etween baseline values of these variables to sustained virologic response (SVR) were determined.

236 which patients are most likely to achieve a sustained virologic response (SVR) with peginterferon/ri

237 The aim of this review was to investigate sustained virologic response (SVR), adherence, discontin

238 orter treatment duration and higher rates of sustained virologic response (SVR), and the role of HCV

239 nd ribavirin therapy are likely to achieve a sustained virologic response (SVR), and we hypothesized

240 Among 31 subjects with sustained virologic response (SVR), anti-HCV became unde

241 The primary outcome was sustained virologic response (SVR), defined as the level

242 is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinf

243 ral agents are associated with high rates of sustained virologic response (SVR), generally exceeding

244 d glucose were minimal and did not differ by sustained virologic response (SVR), HIV, diabetes, or fi

245 for complete early virologic response (EVR), sustained virologic response (SVR), relapse, treatment d

246 therapy for HCV, of whom 106 (45%) achieved sustained virologic response (SVR).

247 ation and different doses of ALV plus RBV on sustained virologic response (SVR).

248 Similar results were found for sustained virologic response (SVR).

249 The primary end point was sustained virologic response (SVR).

250 t and 13 (59%) of treated persons achieved a sustained virologic response (SVR).

251 kinetics of the host response could predict sustained virologic response (SVR).

252 ant variants in patients who did not achieve sustained virologic response (SVR).

253 lations at greater risk of reinfection after sustained virologic response (SVR).

254 been shown to correlate significantly with a sustained virologic response (SVR).

255 8-24 weeks is associated with high rates of sustained virologic response (SVR).

256 nd SOF-based therapies lead to high rates of sustained virologic response (SVR).

257 d treatment, and 119 (91% of initiators) had sustained virologic response (SVR).

258 The primary efficacy end point was sustained virologic response (SVR: HCV RNA <15 IU/mL aft

259 The primary efficacy endpoint was sustained virologic response (SVR; HCV RNA <15 IU/mL aft

260 nd point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA)

261 feron and ribavirin yields approximately 40% sustained virologic responses (SVR).

262 titis C virus (HCV) at week 24 of follow-up (sustained virologic response [SVR] 24) as a primary end

263 tudy sample comprised 903 patients (328 with sustained virologic response [SVR]).

264 untreated HCV RNA positive, 345 treated with sustained virologic response [SVR], 43 during treatment,

265 nt (EOT) liver biopsies from 8 patients (n=7 sustained virologic response [SVR]; n=1 relapse) and unp

266 HCV RNA levels at end of treatment (EOT) for sustained virologic response (SVR12) during interferon-s

267 use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledi

268 n, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety.

269 of follow-up or thereafter was assumed as a sustained virologic response (SVR12).

270 A <15 IU/mL 12 weeks after stopping therapy (sustained virologic response [SVR12]).

271 apse occurred in the W28 arm, resulting in a sustained virologic response (SVR12TND) rate of 100% (12

272 sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those

273 residual risk for disease progression after sustained virologic response, the optimal approach to cu

274 rhosis, 20 started treatment, and 9 achieved sustained virologic response thus far.

275 IV/HCV-coinfected patients, naive or without sustained virologic response to HCV therapy, were includ

276 e 1 infection in patients who have not had a sustained virologic response to prior interferon-based t

277 h HCV genotype 1 infection who had not had a sustained virologic response to prior interferon-based t

278 tients with chronic hepatitis C (CHC) have a sustained virologic response to treatment with pegylated

279 hanges in clonal B cells of MC patients with sustained virologic responses to direct-acting antiviral

280 Disorders, Fourth Edition, quality of life, sustained virologic response, tolerability, and safety.

281 V) infection have demonstrated high rates of sustained virologic response, virologic failure may stil

282 The overall rate of sustained virologic response was 72%.

283 ginterferon was not an option, the rate of a sustained virologic response was 78% (95% confidence int

284 The rate of sustained virologic response was 94% (95% confidence int

285 In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir-vel

286 In the black cohort, a sustained virologic response was achieved in 12 of the 5

287 In addition, a high rate of sustained virologic response was achieved when the two d

288 A sustained virologic response was also observed in 4 pati

289 Sustained virologic response was documented for 10 of 17

290 The criterion for a sustained virologic response was met in 68 of 73 patient

291 In the single-group study, a sustained virologic response was reported in 90% of pati

292 Among patients with genotype 1, a sustained virologic response was reported in 96.4% (95%

293 Overall rates of sustained virologic response were 83% (95% confidence in

294 The rates of sustained virologic response were 99% (95% confidence in

295 The rates of sustained virologic response were high in all treatment

296 High rates of sustained virologic response were observed among patient

297 Rates of sustained virologic response were similar regardless of

298 At 24 weeks after the end of therapy, sustained virologic responses were achieved in 89%, 93%,

299 ts and 98% of 41 patients who did not have a sustained virologic response with HCV protease inhibitor

300 eiving 24-week total therapy, 87% achieved a sustained virologic response with undetectable HCV RNA b